A retrospective, multicentre study assessing efficacy and safety Elotuzumab, pomalidomide, and dexamethasone in very advanced myeloma
Latest Information Update: 09 Feb 2021
At a glance
- Drugs Dexamethasone (Primary) ; Dexamethasone (Primary) ; Elotuzumab (Primary) ; Pomalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 09 Feb 2021 New trial record
- 01 Jan 2021 Results published in the Journal of Cancer Research and Clinical Oncology